Sun Pharmaceutical
add_icon

Sun Pharmaceutical

1,907.00
+2.20
(0.12%)
Market Cap
4,57,553.18 Cr
PE Ratio
39.71
Volume
5,08,287.00
Day High - Low
1,914.70 - 1,900.00
52W High-Low
1,925.10 - 1,548.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
4,57,553.18 Cr
EPS
47.80
PE Ratio
39.71
PB Ratio
5.47
Book Value
348.31
EBITDA
16,182.00
Dividend Yield
0.84 %
Industry
Healthcare
Return on Equity
15.15
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from33 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+87.88 %
+87.88 %
Hold
Hold+3.03 %
+3.03 %
Sell
Sell+9.09 %
+9.09 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Sun Pharmaceutical Industries Ltd will hold its 34th AGM via video conferencing on July 31, 2026. The Board recommended a final dividend of ₹5 per share for FY26.
positive
Sun Pharmaceutical Industries Limited agreed to acquire 100% of Innovcare Lifesciences for ₹271.2 crore to strengthen its product portfolio.
neutral
Sun Pharmaceutical Industries Ltd reported the arrest of Independent Director Gautam Doshi. The company stated the matter is unrelated to its operations.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,907.00
#1 4,57,553.18
#6 39.71
#1 58,220.10
#7 6.38
#1 11,565
#3 25.80
69.58
6,788.50
1,80,213.35
69.89
10,560.00
8.73
2,520
13.44
55.41
4,805.30
1,62,633.19
75.43
13,886.20
20.34
2,138
-26.91
70.39
1,461.10
1,18,034.28
30.51
29,044.60
2.24
3,870
-55.32
66.80
1,151.30
1,15,847.72
22.41
26,719.70
13.65
5,242
7.82
66.88
2,488.10
1,13,764.03
#1 21.14
27,487.50
19.98
5,345
#1 87.72
71.73
1,359.80
1,13,498.30
27.60
35,058.60
3.90
4,158
-86.05
67.04
2,528.00
1,04,405.38
53.93
14,277.60
12.03
1,750
31.75
60.79
1,600.00
92,060.46
26.86
33,384.70
3.21
3,376
1.99
70.76
1,518.10
81,955.63
93.55
6,867.80
#1 22.01
890
21.18
71.63
Growth Rate
Revenue Growth
6.38 %
Net Income Growth
5.32 %
Cash Flow Change
15.96 %
ROE
5.43 %
ROCE
14.46 %
EBITDA Margin (Avg.)
-14.64 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
6,493
6,691
6,973
7,260
7,622
8,164
7,869
7,805
7,050
6,319
6,845
6,727
7,014
7,339
7,198
7,850
7,326
8,472
8,150
8,159
8,180
7,640
9,019
9,124
8,575
9,822
9,780
10,247
9,500
10,646
10,894
11,274
11,099
11,990
12,297
12,407
12,419
13,057
13,618
13,903
13,429
14,251
14,875
16,048
15,018
Expenses
5,318
5,679
5,000
4,877
5,382
5,335
5,092
5,472
5,590
6,064
5,275
5,200
5,294
5,618
6,621
5,587
6,147
6,379
6,334
6,314
7,083
9,375
6,360
6,431
7,147
7,529
6,996
7,257
11,042
7,877
7,996
8,237
8,300
8,932
9,013
8,974
9,049
9,045
9,352
9,983
9,604
10,368
9,951
11,062
10,658
EBITDA
1,175
1,012
1,973
2,383
2,240
2,829
2,776
2,333
1,460
255
1,570
1,528
1,720
1,721
577
2,263
1,179
2,094
1,816
1,845
1,098
-1,736
2,659
2,693
1,427
2,293
2,784
2,990
-1,542
2,769
2,899
3,037
2,799
3,058
3,284
3,433
3,370
4,012
4,266
3,920
3,824
3,883
4,924
4,986
4,361
Operating Profit %
13 %
13 %
27 %
31 %
27 %
33 %
34 %
29 %
18 %
2 %
20 %
21 %
21 %
21 %
3 %
27 %
13 %
23 %
20 %
21 %
12 %
-25 %
25 %
27 %
16 %
22 %
27 %
26 %
-18 %
26 %
26 %
26 %
23 %
24 %
25 %
26 %
23 %
28 %
29 %
26 %
25 %
25 %
31 %
28 %
27 %
Depreciation
462
240
258
251
288
316
304
307
338
347
359
339
455
402
427
471
454
457
473
547
575
496
499
532
554
503
530
554
557
588
610
660
672
651
633
622
650
655
626
631
664
701
730
732
776
Interest
135
135
158
128
103
135
54
167
45
109
157
95
155
131
130
145
150
104
84
63
52
52
33
26
30
35
36
19
37
14
19
46
93
81
49
35
74
62
69
52
49
75
100
78
86
Profit Before Tax
591
872
1,572
2,040
2,087
2,628
2,930
2,102
1,389
-159
1,114
1,148
1,376
1,274
112
1,730
694
1,647
1,433
1,351
577
-2,184
2,206
2,163
903
1,804
2,287
2,466
-2,076
2,285
2,412
2,472
2,240
2,481
2,791
3,000
2,816
3,424
3,598
3,476
3,254
3,173
4,168
4,227
3,551
Tax
-596
115
272
100
424
360
458
380
3
164
113
792
-187
88
272
269
-26
151
270
332
85
242
263
250
61
400
200
340
152
191
157
291
257
476
406
440
157
563
561
563
1,100
880
1,043
846
842
Net Profit
1,186
757
1,299
1,940
1,663
2,268
2,471
1,722
1,386
-323
1,002
356
1,563
1,186
-160
1,461
721
1,497
1,163
1,019
493
-2,426
1,943
1,913
842
1,404
2,086
2,126
-2,227
2,093
2,256
2,181
1,983
2,006
2,385
2,561
2,659
2,861
3,037
2,913
2,154
2,293
3,125
3,381
2,710
EPS in ₹
3.70
2.30
4.30
6.40
5.90
8.50
9.30
6.10
5.20
-1.77
3.80
1.34
5.60
4.41
-1.12
5.18
2.65
5.78
4.43
3.81
1.67
-6.90
7.56
7.72
3.70
6.00
8.50
8.60
-9.50
8.60
9.40
9.00
8.30
8.40
9.90
10.50
11.10
11.80
12.70
12.10
9.00
9.50
13.00
14.00
11.30

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
49,028
55,530
61,410
64,516
64,694
68,253
67,667
69,808
80,744
85,500
92,101
1,08,785
Fixed Assets
12,683
15,872
17,675
18,853
21,837
22,847
21,553
22,665
24,065
23,248
22,586
26,041
Current Assets
29,122
29,941
32,954
31,636
31,069
31,654
30,442
34,865
39,862
43,433
52,594
63,860
Capital Work in Progress
2,039
2,175
2,801
2,465
1,411
1,220
1,567
1,287
4,973
5,354
6,644
1,381
Investments
2,117
1,830
1,192
7,143
7,903
10,143
9,612
12,849
14,824
15,026
18,354
11,493
Other Assets
32,189
35,653
39,742
36,056
33,544
34,042
34,935
33,007
36,881
41,872
44,517
31
Total Equity & Liabilities
49,028
55,530
61,410
64,516
64,694
68,253
67,667
69,808
80,744
85,500
92,101
1,08,785
Current Liabilities
16,353
13,144
17,887
19,864
17,340
15,706
16,146
17,208
19,906
16,984
18,194
22,622
Non Current Liabilities
4,186
5,319
3,093
2,454
2,632
3,421
2,041
1,533
1,522
1,390
1,420
2,283
Total Equity
28,489
37,068
40,431
42,198
44,723
49,125
49,480
51,066
59,316
67,126
72,486
83,570
Reserve & Surplus
25,383
32,741
36,400
38,074
41,169
45,025
46,223
47,771
55,755
63,427
71,978
83,330
Share Capital
207
241
240
240
240
240
240
240
240
240
240
240

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
2,927
848
611
-736
-844
-1,386
596
-1,765
116
4,662
983
Investing Activities
-1,502
-3,949
-4,186
-3,104
-310
-2,225
407
-5,556
-7,220
-763
-5,183
Operating Activities
5,616
6,686
7,082
3,907
2,196
6,555
6,170
8,985
4,959
12,135
14,072
Financing Activities
-1,187
-1,889
-2,285
-1,539
-2,731
-5,715
-5,981
-5,194
2,376
-6,710
-7,906

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
54.48 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.79 %
0.00 %
17.72 %
17.23 %
18.02 %
18.05 %
17.96 %
17.26 %
16.55 %
16.12 %
15.93 %
DIIs
21.59 %
21.93 %
21.67 %
20.94 %
19.94 %
19.57 %
18.60 %
19.14 %
19.24 %
19.75 %
19.67 %
17.97 %
18.83 %
19.28 %
18.61 %
18.55 %
18.70 %
19.50 %
20.24 %
20.82 %
21.11 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.34 %
7.21 %
6.79 %
6.68 %
6.49 %
6.31 %
5.91 %
5.76 %
5.70 %
5.65 %
5.56 %
5.41 %
5.44 %
5.57 %
5.43 %
5.47 %
5.42 %
5.35 %
5.53 %
5.40 %
5.30 %
Others
16.60 %
16.38 %
17.05 %
17.90 %
19.09 %
19.64 %
21.01 %
20.63 %
20.58 %
20.12 %
3.51 %
22.13 %
3.53 %
3.44 %
3.46 %
3.46 %
3.45 %
3.42 %
3.20 %
3.18 %
3.18 %
No of Share Holders
0
7,09,045
7,57,366
6,75,908
6,80,800
6,62,384
6,47,167
6,43,512
6,25,252
6,24,561
6,16,588
6,12,626
6,31,392
6,73,217
6,57,317
6,89,623
7,04,983
7,23,770
7,43,877
7,10,900
6,90,957

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 3.5 2 2.75 4 7.5 10 11.5 13.5 16 0.00
Dividend Yield (%) 0.71 0.42 0.78 0.67 0.82 1.01 0.71 0.78 0.91 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
31 Jul 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
31 Jul 2026 1,786.40 1,904.80
07 Jul 2026 DIVIDEND Dividend
5.00 /share
07 Jul 2026 1,891.15 1,904.80
10 Feb 2021 DIVIDEND Dividend
5.50 /share
09 Feb 2021 564.35 623.60
25 Aug 2021 DIVIDEND Dividend
2.00 /share
23 Aug 2021 703.80 771.35
10 Feb 2022 DIVIDEND Dividend
7.00 /share
09 Feb 2022 827.35 886.45
22 Aug 2022 DIVIDEND Dividend
3.00 /share
19 Aug 2022 903.90 901.35
08 Feb 2023 DIVIDEND Dividend
7.50 /share
08 Feb 2023 1,050.90 1,005.65
28 Jul 2023 DIVIDEND Dividend
4.00 /share
28 Jul 2023 945.00 1,134.95
09 Feb 2024 DIVIDEND Dividend
8.50 /share
09 Feb 2024 1,371.60 1,500.25
12 Jul 2024 DIVIDEND Dividend
5.00 /share
12 Jul 2024 1,541.15 1,583.25
05 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
05 Aug 2024 1,520.65 1,731.65
28 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Oct 2024 1,916.85 1,860.40
21 Jan 2025 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
21 Jan 2025 1,806.20 1,778.25
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jan 2025 1,756.85 1,739.10
06 Feb 2025 DIVIDEND Dividend
10.50 /share
06 Feb 2025 1,739.10 1,753.40
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 May 2025 1,744.85 1,731.60
07 Jul 2025 DIVIDEND Dividend
5.50 /share
07 Jul 2025 1,731.60 1,676.65
31 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
31 Jul 2025 1,731.60 1,734.95
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jul 2025 1,663.15 1,734.95
05 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2025 1,668.50 1,690.00
31 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jan 2026 1,673.55 1,595.00
05 Feb 2026 DIVIDEND Dividend
11.00 /share
05 Feb 2026 1,595.00 1,704.00
22 May 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 May 2026 1,847.90 1,891.15

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication9 days ago
Closure of Trading Window10 days ago
Announcement under Regulation 30 (LODR)-AcquisitionJun 20, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 16, 2026
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015Jun 14, 2026
Intimation Of Record Date For The Purpose Of Final Dividend For FY 2025-26Jun 12, 2026
Corporate Action-Board to consider DividendJun 11, 2026
Intimation Of 34Th Annual General Meeting And Record Date For Final Dividend And Connected MattersJun 11, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 29, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2026
Filing Of Application For Reclassification With Stock ExchangesMay 26, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 26, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 25, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 23, 2026
Investor Call Audio RecordingMay 22, 2026
Additional Outcome Of The Board MeetingMay 22, 2026
Board Meeting Outcome for Recommendation Of Final DividendMay 22, 2026
Financial Results For The Quarter And Year Ended 31 March 2026May 22, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 20, 2026
Intimation For Receipt Of Requests For Reclassification Of Shareholder CategoryMay 14, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateMay 12, 2026
Board Meeting Intimation for Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended 31 March 2026 And Recommendation Of Final Dividend For FY 2025-26May 11, 2026
Completion And Result Of Postal Ballot Dated 07 April 2026May 08, 2026
Announcement under Regulation 30 (LODR)-Credit RatingMay 07, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 05, 2026
Investor Call Audio RecordingApr 27, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationApr 27, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 27, 2026
Announcement under Regulation 30 (LODR)-AcquisitionApr 27, 2026
Incorporation Of A Subsidiary CompanyApr 24, 2026
Completion And Results Of Postal Ballot Dated 17 March 2026Apr 17, 2026
Rumour verification - Regulation 30(11)Apr 10, 2026
Clarification sought from Sun Pharmaceutical Industries LtdApr 10, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 08, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotApr 07, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Announcement under Regulation 30 (LODR)-Change in DirectorateApr 04, 2026
Updates On Fibromun And NidlegyMar 28, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 27, 2026
Closure of Trading WindowMar 25, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 21, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 18, 2026
Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 17, 2026
Shareholder Satisfaction Survey On RTA ServicesMar 17, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 16, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 24, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 04, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2026

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
ICICI Prudential Active Momentum Fund Direct-Growth
0.00%
-109008
-1.03%
-3.90%
Motilal Oswal Contra Fund Direct-Growth
2.29%
33974
2.29%
2.29%
ICICI Prudential Quality Fund Direct-Growth
3.45%
-24007
-0.18%
-1.41%
Helios Arbitrage Fund Direct-Growth
4.03%
14000
-2.80%
4.03%
JioBlackRock Arbitrage Fund Direct-Growth
0.52%
11200
0.36%
0.24%
The Wealth Company Arbitrage Fund Direct-Growth
0.00%
-10500
-1.23%
0.00%
Kotak Active Momentum Fund Direct-Growth
1.63%
8734
0.06%
-0.05%
Old Bridge Arbitrage Fund Direct-Growth
0.07%
-4200
-0.51%
0.07%
Parag Parikh Large Cap Fund Direct-Growth
1.42%
3603
0.01%
-0.04%
Invesco India BSE Sensex Index Fund Direct-Growth
2.17%
2052
2.17%
2.17%
Groww Multi Asset Allocation Fund Direct-Growth
0.73%
1677
0.06%
0.08%
JioBlackRock Sector Rotation Fund Direct-Growth
1.42%
1663
0.13%
-0.02%
DSP Nifty Healthcare Index Fund Direct-Growth
18.27%
1198
-0.67%
-1.02%
JioBlackRock Nifty 50 Index Fund Direct-Growth
1.76%
1098
0.02%
-0.05%
JioBlackRock Large Cap Fund Direct-Growth
1.55%
980
0.32%
1.55%
HDFC Nifty Top 20 Equal Weight Index Fund Direct-Growth
5.07%
690
0.11%
-0.05%
The Wealth Company Balanced Advantage Fund Direct-Growth
1.47%
-611
-0.30%
-0.38%
Zerodha Nifty 50 Index Fund Direct-Growth
1.76%
527
0.02%
-0.06%
UTI Nifty500 Shariah Index Fund Direct-Growth
3.34%
373
-0.08%
-0.25%
Nippon India Nifty India Manufacturing Index Fund Direct-Growth
4.59%
-241
-0.15%
-0.49%
Zerodha BSE SENSEX Index Fund Direct-Growth
2.20%
190
0.03%
-0.03%
Axis BSE India Sector Leaders Index Fund Direct-Growth
1.93%
-164
0.03%
-0.11%
HDFC BSE India Sector Leaders Index Fund Direct-Growth
1.93%
-118
0.02%
-0.12%
SBI Nifty100 Low Volatility 30 Index Fund Direct-Growth
3.40%
-112
0.00%
-0.14%
Bandhan BSE India Sector Leaders Index Fund Direct-Growth
1.94%
-106
0.03%
-0.11%

Technical Indicators

RSI(14)
Neutral
69.58
ATR(14)
Volatile
31.68
STOCH(9,6)
Neutral
66.29
STOCH RSI(14)
Overbought
81.95
MACD(12,26)
Bullish
5.72
ADX(14)
Strong Trend
26.45
UO(9)
Bearish
41.49
ROC(12)
Uptrend And Accelerating
5.78
WillR(14)
Overbought
-15.32

About Sun Pharmaceutical

Sun Pharmaceutical Industries Limited is a global specialty generic pharmaceutical company based in India. It manufactures and markets a wide range of pharmaceutical formulations including generics, branded generics, complex products, over-the-counter drugs, and active pharmaceutical ingredients. The company has a diverse portfolio covering multiple therapeutic areas and dosage forms. Sun...more
Chairperson NameDilip S Shanghvi